Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Ltd
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study of mepolizumab (study medication) as add-on therapy in subjects who require daily oral corticosteroids to treat their severe asthma
To compare the effects of mepolizumab adjunctive therapy with placebo on reducing the use of maintenance oral corticosteroids (OCS) in systemic corticosteroid dependent subjects with severe refractory...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer
To compare the progression-free survival (as assessed by independent central disease assessment review) of taxane based chemotherapy plus lapatinib for 24 weeks followed by single agent lapatinib ther...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Clinical study to compare long term use of Fluticasone Propionate alone to Fluticasone Propionate and Salmeterol together in Asthma patients
The primary objectives of this study were to demonstrate that fluticasone propionate/salmeterol combination product (FSC) 100/50mcg BID (available as ADVAIR DISKUS®) was superior to montelukast (MON) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting Beta2-agonist
The primary objective is to evaluate the efficacy, dose response and safety of four doses of GSK 2190915 (10mg, 30mg, 100mg and 300mg)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine
To assess the safety and tolerability of eltrombopag versus placebo in subjects receiving standard induction therapy for acute myeloid leukemia (AML)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation
To determine if an on demand dosing of 50 or 150 mg of GSK557296 demonstrates superior efficacy with respect to duration of IELT during an 8 week study period compared to placebo in men with premature...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects with mild to moderate Alzheimer’s Disease (AD)
To compare changes in cerebral glucose metabolism in subjects receiving a 12- month course of Rosiglitazone XR to those receiving placebo, including the time course of any changes.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A phase II clinical study to assess the effectiveness, safety, tolerability and pharmacokinetics of inhaled GSK2339345 in patients with chronic cough using an aqueous droplet inhaler
EFFICACY: To evaluate the effect of a single dose of GSK2339345, administered on two occasions, four hours apart, versus placebo on objective cough counts in patients with chronic idiopathic cough.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Study PXN110527: The investigation of the efficacy and pharmacokinetics of XP13512 in subjects with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had an inadequate response to gabapentin treatment
The primary objective of the study is to investigate the difference between two doses of XP13512 (3600 mg/day vs. 1200 mg/day) on pain intensity.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimised background therapy (OBT) regimen versus placebo plus OBT over 48 weeks in HIV-1 infected, treatment-experienced subjects with drug-resistant CCR5-tropic virus
•To demonstrate the superiority of GW873140 400mg BID plus optimised background therapy (OBT) compared to placebo plus OBT, as measured by the difference in plasma HIV-1 RNA average area under the cur...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant